Navigation Links
Solid Second Quarter 2013 for Gerresheimer
Date:7/9/2013

DUESSELDORF, Germany, July 10, 2013 /PRNewswire/ --

  • Second-quarter revenues up 4.2% to EUR 327.1m
  • Adjusted EBITDA of EUR 59.8m slightly above prior-year quarter (up 0.5%)
  • Adjusted net income at EUR 21.5m (up 0.9%)
  • Adjusted earnings per share on a par with prior-year quarter, at EUR 0.63
  • Guidance for financial year 2013 made more specific

Gerresheimer AG, one of the leading partners to the pharma and healthcare industry worldwide, generated solid figures in the second quarter of the 2013 financial year."Our strategy is geared to sustained, profitable growth.We continue to be successful in implementing that strategy.In the second quarter, we saw notable growth particularly in our medical systems for drug delivery and in pharmaceutical plastic packaging.Our latest acquisitions in India are also developing very well," said Uwe Röhrhoff, CEO of Gerresheimer AG.

Gerresheimer increased revenues in the second quarter of financial year 2013 (financial year from December 1 to November 30) by 4.2% to EUR 327.1m. The revenue growth mainly reflects strong business in the Plastic Systems Division with pharmaceutical primary packaging, insulin pens and inhalers. Triveni, an Indian company specializing in pharmaceutical plastic packaging acquired in December 2012, likewise contributed to the increase in revenues. The Moulded Glass Division generated healthy growth rates notably with the sale of cosmetic glass packaging.

Gerresheimer recorded adjusted EBITDA of EUR 59.8m in the second quarter of 2013, an increase of 0.5% on the prior-year quarter. The adjusted EBITDA margin was 18.3%, below the 19.0% margin in the comparative period. The main causes of the decreased margin comprised the anticipated high cost of improving the production of prefillable syringes at a German plant and quality problems in the manufacture of glass ampoules identified at a Mexican plant during the second quarter.

Adjusted net income for the second quarter came to EUR 21.5m, 0.9% more than in the prior-year quarter (EUR 21.3m). Adjusted earnings per share were exactly on a par with the prior-year quarter, at EUR 0.63. Gerresheimer's capital expenditure in the second quarter of 2013 was EUR 33.4m, EUR 2.0m more than a year earlier.

Outlook

For financial year 2013, Gerresheimer continues to expect revenue growth of 5% to 6% at constant exchange rates. For adjusted EBITDA, the company has made its guidance more specific with a range of between EUR 245m and EUR 250m. Attainment of the revenue growth guidance of 5% to 6% would correspond to a potential adjusted EBITDA margin range of approximately 19.0% to 19.4%. Largely due to the healthy growth prospects in the Plastic Systems Division, capital expenditure in financial year 2013 will represent some 9% to 10% of exchange rate adjusted revenues.

- Cross reference: The press release including Group Key Figures is available at http://ots.de/AyUB2 -

The online annual report is available at: http://annualreport2012.gerresheimer.com

Contact:
Jens Kürten
Director Corporate Communication & Marketing
Phone: +49-211-6181-250
Fax:   +49-211-6181-241
E-Mail: j.kuerten@gerresheimer.com
Internet: http://www.gerresheimer.com


'/>"/>
SOURCE Gerresheimer AG
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Confluent Translations Consolidates Marketing Efforts
2. Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine
3. Sunset World will Consolidate its Presence in the Mexican Caribbean in 2013
4. Researchers nanoweld by applying light to aligned nanorods in solid materials
5. China Cord Blood Corporation Announces Completion of Corporate Structure Consolidation
6. NSG Precision Leads Industry with Solid-State Nano-Deposition Calibration Standards
7. Florida-Based Team Gemini Signs Recycling Facility Agreement with Solid Waste Authority of Central Ohio
8. China Cord Blood Corporation to Further Consolidate its Corporate Structure
9. A KAIST research team has developed a high performance flexible solid state battery
10. Karyopharm Therapeutics Announces Multiple Presentations on Selective Inhibitors of Nuclear Export (SINE) in Solid and Hematologic Malignancy Models and Spontaneous Canine Cancers at the American Association of Cancer Research (AACR) Meeting
11. Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 18, 2017 , ... Researchers from a new study are stating that if levels ... prostate cancer treatment, this indicates there is still remaining prostate cancer cells that are more ... PSA test has always been an indicator of whether a man’s prostate cancer is ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... 2017, to sell research and genetic testing lab equipment from two different leading institutes. ... Northwest and Northeast regions of the United States. This 1-day online auction will ...
(Date:1/18/2017)... ... January 18, 2017 , ... Thirty-six startup companies in University City ... Pennsylvania Department of Community and Economic Development in 2016 as part of the Keystone ... University City Keystone Innovation Zone and represent the highest number of awards to the ...
(Date:1/18/2017)... , Jan. 18, 2017  HUYA Bioscience International, (HUYA), ... China,s pharmaceutical innovations, announced today a ... Innovation and Investment Company (referred to as CAS Innovation). ... innovations discovered by leading scientists at CAS to meet ... HUYA is the first company to have recognized ...
Breaking Biology Technology:
(Date:1/18/2017)... 2017  In vitro diagnostic (IVD) companies were very ... (M&A), and Kalorama Information expects that trend to continue ... shifting. Generally, uncertainty in reimbursement and healthcare reform in ... changed the acquisitions landscape. Instead of looking to buy ... partners outside of their home country and also to ...
(Date:1/12/2017)... -- Trovagene, Inc. (NASDAQ: TROV ), a developer ... it has signed agreements with seven strategic partners across ... Middle East for commercialization of the Trovera™ ... of international distribution agreements for Trovagene,s CLIA based liquid ... The initial partners will introduce Trovagene,s liquid biopsy tests ...
(Date:1/11/2017)... Jan. 11, 2017 Intoxalock, a leading ignition ... release of its patent-pending calibration device. With this new ... calibrations, securely upload data logs and process repairs at ... "Fighting drunk driving through the application of ... at large, but also for the customer who can ...
Breaking Biology News(10 mins):